These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 18591268)

  • 21. Pulmonary Delivery of Isoniazid in Nanogel-Loaded Chitosan Hybrid Microparticles for Inhalation.
    Omar SM; Maziad NA; El-Tantawy NM
    J Aerosol Med Pulm Drug Deliv; 2019 Apr; 32(2):78-87. PubMed ID: 30526251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhalable Particles for "Pincer Therapeutics" Targeting Nitazoxanide as Bactericidal and Host-Directed Agent to Macrophages in a Mouse Model of Tuberculosis.
    Gupta A; Meena J; Sharma D; Gupta P; Gupta UD; Kumar S; Sharma S; Panda AK; Misra A
    Mol Pharm; 2016 Sep; 13(9):3247-55. PubMed ID: 27463245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rifabutin loaded inhalable β-glucan microparticle based drug delivery system for pulmonary TB.
    Ahmad F; Ahmad S; Upadhyay TK; Singh S; Khubaib M; Singh J; Saeed M; Ahmad I; Al-Keridis LA; Sharma R
    Sci Rep; 2024 Jul; 14(1):16437. PubMed ID: 39013991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
    Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
    J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis.
    Jayaram R; Shandil RK; Gaonkar S; Kaur P; Suresh BL; Mahesh BN; Jayashree R; Nandi V; Bharath S; Kantharaj E; Balasubramanian V
    Antimicrob Agents Chemother; 2004 Aug; 48(8):2951-7. PubMed ID: 15273105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhalable Fucoidan Microparticles Combining Two Antitubercular Drugs with Potential Application in Pulmonary Tuberculosis Therapy.
    Cunha L; Rodrigues S; Rosa da Costa AM; Faleiro ML; Buttini F; Grenha A
    Polymers (Basel); 2018 Jun; 10(6):. PubMed ID: 30966670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages.
    Zhou H; Zhang Y; Biggs DL; Manning MC; Randolph TW; Christians U; Hybertson BM; Ng KY
    J Control Release; 2005 Oct; 107(2):288-99. PubMed ID: 16009444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid.
    Conte JE; Golden JA; McQuitty M; Kipps J; Duncan S; McKenna E; Zurlinden E
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2358-64. PubMed ID: 12121905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rifabutin-loaded solid lipid nanoparticles for inhaled antitubercular therapy: Physicochemical and in vitro studies.
    Gaspar DP; Faria V; Gonçalves LM; Taboada P; Remuñán-López C; Almeida AJ
    Int J Pharm; 2016 Jan; 497(1-2):199-209. PubMed ID: 26656946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhalable poly(lactic-co-glycolic acid) (PLGA) microparticles encapsulating all-trans-Retinoic acid (ATRA) as a host-directed, adjunctive treatment for Mycobacterium tuberculosis infection.
    O'Connor G; Krishnan N; Fagan-Murphy A; Cassidy J; O'Leary S; Robertson BD; Keane J; O'Sullivan MP; Cryan SA
    Eur J Pharm Biopharm; 2019 Jan; 134():153-165. PubMed ID: 30385419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual antitubercular drug loaded liposomes for macrophage targeting: development, characterisation,
    Shrivastava P; Gautam L; Sharma R; Dube D; Vyas S; Vyas SP
    J Microencapsul; 2021 Mar; 38(2):108-123. PubMed ID: 33267623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HLA-DRB1*1501 and VDR polymorphisms and survival of Mycobacterium tuberculosis in human macrophages exposed to inhalable microparticles.
    Singh AK; Abhimanyu ; Yadav AB; Sharma S; Garg R; Bose M; Misra A
    Pharmacogenomics; 2013 Apr; 14(5):531-40. PubMed ID: 23556450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles.
    Dutt M; Khuller GK
    J Antimicrob Chemother; 2001 Jun; 47(6):829-35. PubMed ID: 11389115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
    Benator DA; Weiner MH; Burman WJ; Vernon AA; Zhao ZA; Khan AE; Jones BE; Sandman L; Engle M; Silva-Trigo C; Hsyu PH; Becker MI; Peloquin CA;
    Pharmacotherapy; 2007 Jun; 27(6):793-800. PubMed ID: 17542762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of rifabutin alone or in combination with isoniazid in preventive therapy of mouse tuberculosis.
    Jabès D; Della Bruna C; Rossi R; Olliaro P
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2346-50. PubMed ID: 7840568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Biodistribution of Rifabutin Polymeric Transport Form].
    Kuznetsova IG; Dubovik EG; Dubovik NS; Komarov TN; Medvedev YV; Menshikova LA; Severin SE; Shohin IE; Yarushok TA
    Vestn Ross Akad Med Nauk; 2015; (3):366-71. PubMed ID: 26495727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis.
    Weiner M; Benator D; Peloquin CA; Burman W; Vernon A; Engle M; Khan A; Zhao Z;
    Clin Infect Dis; 2005 Nov; 41(9):1343-9. PubMed ID: 16206114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug.
    Jia L; Tomaszewski JE; Hanrahan C; Coward L; Noker P; Gorman G; Nikonenko B; Protopopova M
    Br J Pharmacol; 2005 Jan; 144(1):80-7. PubMed ID: 15644871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carrageenan from red algae: an application in the development of inhalable tuberculosis therapy targeting the macrophages.
    Rodrigues S; Cunha L; Rico J; Rosa da Costa AM; Almeida AJ; Faleiro ML; Buttini F; Grenha A
    Drug Deliv Transl Res; 2020 Dec; 10(6):1675-1687. PubMed ID: 32562253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolerability of twice-weekly rifabutin-isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV-infected subjects: a pilot study.
    Matteelli A; Olliaro P; Signorini L; Cadeo G; Scalzini A; Bonazzi L; Caligaris S; Tomasoni L; Tebaldi A; Carosi G
    Int J Tuberc Lung Dis; 1999 Nov; 3(11):1043-6. PubMed ID: 10587327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.